Perfecting in vitro mammalian display for antibody selection

Vaccinex’s proprietary full-length human antibody discovery engine, ActivMAb, integrates selection and manufacturing in the same mammalian host to streamline development. To download the full article, please sign in.

Page of
Go to the profile of Vaccinex


Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases. The Company has completed phase 1 clinical trials in solid tumors and multiple sclerosis and is currently engaged in a phase 2 clinical trial in Huntington’s disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed in mammalian cells and have desirable solubility and stability properties. Vaccinex is based in Rochester, New York, USA.

Comments are disabled